Skip to main content
Premium Trial:

Request an Annual Quote

Go On, Admit Defeat

Gene Essence, says Daniel MacArthur, is a good example of those personal genomics companies that will hopefully fall to the cease-and-desist guns. Aside from the reassuring fact that the company uses Affy chips, "it's all downhill from there." Their service is too expensive, the demo page is confusing, the user manual is unhelpful, and there is no evidence of a sure correlation between SNPs and disease risk. "In other words, the company provides a series of alarming and confusing predictions, and then simply tells you they don't necessarily mean anything," MacArthur says at Genetic Future. "There should be a minimum standard of validation and information reporting."

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.